Company news
Xilio Therapeutics, Inc. (NASDAQ:XLO) news
Xilio Therapeutics, Inc. news releases on 6ix. Latest, Oct 2, 2026: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releases & updates
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 1, 2026
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
September 28, 2026
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
August 12, 2026
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
June 29, 2026
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
May 12, 2026
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 7, 2026
May 11, 2026
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 7, 2026
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
April 17, 2026
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
April 15, 2026
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
March 22, 2026
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
March 17, 2026
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
March 11, 2026
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
March 2, 2026
Xilio Therapeutics Announces Pricing of Underwritten Offering
February 10, 2026
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
January 8, 2026
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results
November 13, 2025
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
November 7, 2025
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
November 7, 2025
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 3, 2025
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting
October 30, 2025
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
October 3, 2025
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
September 9, 2025
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results
August 14, 2025
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
August 4, 2025
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors
June 10, 2025
Xilio Therapeutics Announces Closing of $50.0 Million Public Offering
June 5, 2025
Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering
June 2, 2025
Xilio Therapeutics Announces Proposed Public Offering
June 2, 2025
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
May 31, 2025
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results
May 8, 2025
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 2, 2025
Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting
April 23, 2025
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results
March 11, 2025
Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
February 24, 2025
Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs
February 11, 2025
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 2, 2025
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
January 20, 2025
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 9, 2025
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer
December 15, 2024
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
November 6, 2024
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
October 3, 2024
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
August 7, 2024
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
June 12, 2024
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
May 13, 2024
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
March 31, 2024
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
March 27, 2024
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
December 6, 2023
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
November 8, 2023
Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
November 2, 2023